Skip to main content

Table 2 Clinical characteristics of study population grouped by glycemic control

From: Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control

 

HbA1c ≤6.5%

HbA1c >6.5%

 

n = 50

n = 220

P value

Age (years)

68 ± 12

67 ± 12

0.66

Gender (men,%)

40 (80)

173 (79)

0.85

BMI (Kg/m2)

27 ± 4

27 ± 4

0.60

Hypertension (%)

43 (86)

182 (83)

0.67

Smoking (%)

7 (14)

46 (21)

0.33

Hypercholesterolemia (%)

19 (38)

101 (46)

0.35

CAD (%)

36 (72)

175 (80)

0.26

Cholesterol (mg/dl)

   

   Total

159 ± 33

164 ± 33

0.39

   HDL-Cholesterol

44 ± 16

40 ± 9

0.04

   LDL-Cholesterol

95 ± 27

99 ± 29

0.40

Triglyceride (mg/dl)

138 ± 68

170 ± 105

0.04

Creatinine (mg/dl)

1.4 ± 1.0

1.4 ± 1.1

0.96

eGFR (ml/min per 1.73 m2)

69 ± 29

69 ± 32

0.88

Fasting blood sugar (mg/dl)

113 ± 25

143 ± 51

<0.01

ADMA (μmol/l)

0.47 ± 0.10

0.46 ± 0.08

0.27

SDMA (μmol/l)

0.70 ± 0.37

0.81 ± 0.60

0.33

L-arginine (μmol/l)

87 ± 30

88 ± 29

0.83

L-arginine/ADMA

188 ± 69

195 ± 67

0.52

HbA1c

6.1 ± 0.3

8.2 ± 1.5

<0.01

Hypoglycemic treatments

   

 Sulfaurea (%)

17 (34)

113 (51)

0.03

 Metformin (%)

29 (58)

130 (59)

1.00

 TZD (%)

1 (2)

17 (8)

0.21

 Acarbose (%)

2 (4)

30 (14)

0.09

 Insulin (%)

5 (10)

62 (28)

<0.01

 Insulin + OHA (%)

1 (2)

22 (10)

0.09

  1. BMI: body mass index; CAD: coronary artery disease; eGFR: estimated glomerular filtration rate; OHA: oral hypoglycemic agent; TZD: thiazolidinedie.